Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07414368
Enrolling by invitation Observational

Case Series of StimLabs Dehydrated Human Umbilical Cord Particulate for Acute and Chronic Wounds

NCT07414368 · tracked via the Priya Life Science USA tracker
Sponsor
StimLabs
Phase
Observational
Started
2026-02-11
Last updated
2026-04-28

Condition(s) studied

Chronic UlcersDiabetic Foot Ulcers (DFU)DFUUlcer

Investigational drug(s) / intervention(s)

Corplex P is used to cover, protect, and provide a moist wound environment

Corplex P is used to cover, protect, and provide a moist wound environment: Corplex P is derived from human birth tissue and used in wound management to cover, protect, and provide a moist wound environment.

Study summary

The purpose of this observational case series is to assess the use of Corplex P as a resorbable particulate device used to cover, protect, and provide a moist wound environment when added to the standard of care treatment of hard-to-heal wounds.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All consecutive subjects that received a Corplex P device application during wound management in the following retrospective cohort between February 2024 and November 2025. Exclusion Criteria: * Subjects not receiving an initial Corplex P application during treatment

Primary outcome measure(s)

  • The proportion of target ulcers achieving complete wound closure during the observational period — 1-12 weeks
    Determine the percent (%) of target ulcers achieving complete wound closure at 12 weeks.

Trial sites (1)

FacilityCityRegionStatus
Family Foot & Ankle Specialists, LLC Bridgeport Connecticut

More StimLabs trials in the USA

Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs Recruiting

Other trials for the same condition

Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial. Recruiting
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers Recruiting
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers Recruiting
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy Recruiting
Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07414368 on ClinicalTrials.gov ↗ ← All trials in the USA